Latigo Biotherapeutics, Inc.
For the period ended Sep 30, 2026. Filed Nov 5, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 5, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
Rule 10b5-1 Trading Arrangements
During the three months ended September 30, 2026, our directors and officers (as defined in Rule 16a-1(f) under the Exchange Act) adopted, modified, or terminated trading plans for the orderly disposition of the Company’s securities as set forth in the table below.
| · Adoption / · Type of Trading Arrangement · Total Shares of | |||||
|---|---|---|---|---|---|
| Termination · Rule · Non-Rule · Common Stock | |||||
| Name and Position · Action · Date · 10b5-1(1) · 10b5-1(2) · to be Sold · Expiration Date | |||||
| Nima Farzan | Adoption | 21-Aug-26 | X | 420,000(3) | 31-Dec-27 |
| Former Director, President and Chief Executive Officer | |||||
| Neha Krishnamohan | Adoption | 21-Aug-26 | X | 68,600(3) | 31-Dec-27 |
| Chief Financial Officer and Chief Business Officer | |||||
(1) Contract, instruction or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act.
(2) "Non-Rule 10b5-1 trading arrangement" as defined in Item 408(c) of Regulation S-K under the Exchange Act.
(3) Pursuant to the terms of a lock-up agreement entered into with the underwriters in connection with the Company’s IPO, none of the securities subject to the trading arrangement will be transferred, sold or otherwise disposed of during the lock-up period, which expires after February 2, 2027.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.